Reprogrammed CD19 CAR-T therapy for B-cell lymphoma and CLL
Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
This project tests a metabolically reprogrammed CD19 CAR-T immune therapy for people with B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11298950 on NIH RePORTER |
What this research studies
If you join, your T cells would be collected and reprogrammed in the lab to blend strong anti-tumor activity with longer-lived, stem-like properties before being engineered to target CD19 and purified for infusion. The approach uses ex vivo programming to create a hybrid Th1/Th17 CAR-T product intended to resist the suppressive tumor environment and survive longer in the body. This is an early-phase (Phase I) clinical effort focused on safety, how the cells behave after infusion, and early signs that the treatment can shrink disease. You would have in-person procedures including leukapheresis, possible conditioning therapy, the CAR-T infusion, and follow-up monitoring at the study site.
Who could benefit from this research
Good fit: Ideal candidates are adults with relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia who are medically able to undergo leukapheresis, lymphodepletion, and CAR-T infusion.
Not a fit: People whose cancers lack CD19, who have uncontrolled infections or severe organ dysfunction, or who cannot undergo the required cell collection and infusion procedures may not benefit from this approach.
Why it matters
Potential benefit: If successful, this could produce longer-lasting and more effective CAR-T responses with fewer relapses for people with CD19-positive NHL or CLL.
How similar studies have performed: Standard CD19 CAR-T therapies have achieved remissions in many B-cell cancer patients, but this specific metabolically reprogrammed Th1/Th17 CD19-CAR-T approach is novel and at an early clinical stage.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Hess, Brian — Medical University of South Carolina
- Study coordinator: Hess, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.